Information Provided By: 
Fly News Breaks for November 2, 2015
SHPG, DYAX
Nov 2, 2015 | 12:53 EDT
Jefferies analyst Biren Amin downgraded Dyax (DYAX) to Hold saying the takeover by Shire (SHPG) should receive regulatory approval. The company may be asked to divest Kalbitor since it competes with Shire's Firazyr as acute treatment for hereditary angioedema attacks, the analyst writes. He does not view Kalbitor as a core part of the deal.
News For DYAX;SHPG From the Last 2 Days
There are no results for your query DYAX;SHPG
